Recurrent Extrapulmonary Neuroendocrine Carcinoma
1 clinical trials · Condition
◉ Watch Recurrent Extrapulmonary Neuroendocrine Carcinoma
| Record | Firm | Date |
|---|---|---|
| Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (NCT05058651) | National Cancer Institute (NCI) | 2022-06-28 |
Track Recurrent Extrapulmonary Neuroendocrine Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.